Amarin (AMRN)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (-0.11%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.78 0.00 (-0.56%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 161 - 180 ( 361 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa FDA-Approval for Expanded Label in CV Risk Reduction Consistent With Our Label Expectations; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Upon Closer Look, What Does EVAPORATE Tell Us?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Cost-effectiveness Results Add Another Notch to the Belt
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Putting Numbers Behind Yesterday?s Positive AdCom Vote
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Let''s Decode the AdCom to Figure Out Label Possibilities
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Get a Head Start on AHA in Philadelphia with Our Prep Material
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
FDA AdCom Focus on Safety and Placebo Effects Suggest Satisfactory Efficacy, in Our View
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Briefing Book Charts a Favorable Path Forward to AdCom Vote
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: Halftime Show of Our Most In-Depth, Differentiated Earnings Yet
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y